1. Pattern of care and clinical outcome of patients with carcinoma endometrium and the impact of central histopathological review on management: A tertiary cancer centre experience
- Author
-
Verma, Rakhi, Gandhi, Ajeet K., Rastogi, Madhup, Mishra, Vachaspati K., Sharma, Vikas, Agarwal, Akash, Shukla, Saumya, Khurana, Rohini, Hadi, Rahat, Srivastava, Anoop K., and Husain, Nuzhat
- Subjects
Diagnosis ,Care and treatment ,Case studies ,Research ,Patient outcomes ,Methods ,Pathological histology -- Research ,Endometrial cancer -- Diagnosis -- Care and treatment -- Case studies ,Radiotherapy -- Methods -- Patient outcomes ,Adjuvant chemotherapy -- Methods -- Patient outcomes ,Cancer -- Adjuvant treatment ,Histology, Pathological -- Research - Abstract
Author(s): Rakhi Verma [1]; Ajeet K. Gandhi (corresponding author) [1]; Madhup Rastogi [1]; Vachaspati K. Mishra [1]; Vikas Sharma [2]; Akash Agarwal [2]; Saumya Shukla [3]; Rohini Khurana [1]; Rahat [...], Purpose/Objective: Endometrial carcinoma (EC) is the third most common gynecological malignancy in India. Recent PORTEC-3 analysis emphasized the role of central histopathological review. We aimed to retrospectively analyze the demographic and histopathological characteristics of EC patients treated at our institute and assess the impact of the central histopathological review on management and also analyze clinical outcomes in this cohort of patients. Materials and Methods: Data of 75 EC patients treated at our center between 2013 and 2022 were retrieved from our departmental archives. Patients were analyzed for demographic details, histopathological findings, details of surgery and histopathology (HPE), results of a review of HPE, adjuvant treatment details, and clinical outcomes. All patients with HPE outside of our institute were reviewed at our center prior to initiation of treatment. In cases of discordance, patients were discussed in the multidisciplinary tumor board for the final treatment decisions. Patients were staged as per International Federation of Gynaecology and Obstetrics 2018. Result: The median age was 57 years (range: 37-74 years). Twenty-seven patients with HPE reported from the outside center were reviewed at our institute and changes were observed in 26 patients (96.3). HPE review changes were observed in terms of histological grade, histological type, myometrial invasion, and lymph node involvement in five (18.5), three (11.1), seven (25.9), and three (42.8), respectively. HPE review leads to changes in the management of 19/26 patients. Stage distribution was I: II: III in 48 (64): 9 (13.3): 18 (24) patients, respectively. The median external beam radiotherapy dose was 50 Gray (range: 45-50.4 Gray at 1.8-2 Gray per fraction). The median brachytherapy dose for patients treated with brachytherapy alone was 7 Gray each for three sessions and in combination with EBRT was 6 Gray each in two sessions. At a median follow-up of 51 months (range: 6-116 months), seven (9.3) patients developed distant metastasis, two (2.7) patients had local plus distant metastasis, and two (2.7) patients had local recurrence. The overall survival and disease-free survival rates at 3 years were 93.5 and 86.7, respectively. Conclusion: EC patients treated at our center have excellent local control rates with a combination of external beam radiotherapy and brachytherapy. The central histopathological review may result in changes impacting patient management and should be routinely done prior to initiation of treatment in EC. Keywords: Brachytherapy, endometrial cancer, external beam radiotherapy
- Published
- 2024
- Full Text
- View/download PDF